Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7955673 | 1.00 | LMNA (0.43) | LMNACYP2C9TDP1 | |
| SCHEMBL14598562 | 0.84 | TDP1 (0.36) | LMNACYP2C9TDP1 | |
| SCHEMBL4378224 | 0.84 | TDP1 (0.36) | LMNACYP2C9TDP1 | |
| SCHEMBL4378227 | 0.84 | TDP1 (0.36) | LMNACYP2C9TDP1 | |
| SCHEMBL5398400 | 0.84 | TDP1 (0.36) | LMNACYP2C9TDP1 | |
| SCHEMBL23559739 | 0.80 | SLC6A3 (0.44) | LMNACYP2C9TDP1 | |
| SCHEMBL15112779 | 0.80 | SLC6A3 (0.44) | LMNACYP2C9TDP1 | |
| SCHEMBL21913572 | 0.80 | SLC6A3 (0.44) | LMNACYP2C9TDP1 | |
| SCHEMBL5394310 | 0.79 | SLC6A3 (0.44) | — | |
| SCHEMBL5394317 | 0.79 | SLC6A3 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | XUANZHU PHARMA CO, LTD. (CN) | 2019-12-17 | — | — | US | disclosed |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | XUANZHU PHARMA CO, LTD. (CN) | 2019-12-17 | — | — | US | disclosed |
| US-20180186807-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | BIOPHARMA CREDIT PLC (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20180186807-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | BIOPHARMA CREDIT PLC (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20180186807-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | BIOPHARMA CREDIT PLC (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-10-26 | — | — | US | disclosed |
| EP-2612860-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2013-07-10 | — | — | EP | disclosed |
| EP-2612860-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2013-07-10 | — | — | EP | disclosed |
| US-6255490-B1 | TREATING DISORDERS ASSOCIATED WITH CHANGES IN CHOLINERGIC ACTIVITY; NON-OPIATE BASED ANALGESIC FOR MODERATE TO SEVERE PAIN EQUALLY OR EXCEEDING THE POTENCY OF OPIATE ANALGESICS, YET LACKING ADDICTIVE SIDE EFFECTS | UNIVERSITY OF VIRGINIA | 2001-07-03 | — | — | US | disclosed |
| US-6117889-A | 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents | UNIVERSITY OF VIRGINIA (US) | 2000-09-12 | — | — | US | disclosed |
| US-6060473-A | 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands | UCB S.A. - DTB (BE) | 2000-05-09 | — | — | US | disclosed |
| EP-0778835-A4 | 7-AZABICYCLO 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIV VIRGINIA (US) | 1999-02-03 | — | — | EP | disclosed |
| EP-0778835-A1 | 7-AZABICYCLO 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF VIRGINIA (US) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996006093-A1 | 7-AZABICYCLO[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF VIRGINIA (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0691971-A1 | 7-AZABICYCLO- 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS | UNIVERSITY OF VIRGINIA (US) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022868-A1 | 7-AZABICYCLO-[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS | UNIVERSITY OF VIRGINIA (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | LMNA 1338/4885CYP2C9 128/4885TDP1 3804/4885 |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | LMNA 1338/4885CYP2C9 128/4885TDP1 3804/4885 |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | NQO2, CHRM1, CHRM2 | LMNA 1338/4885CYP2C9 128/4885TDP1 3804/4885 |
| US-20180186807-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | LMNA 823/4885CYP2C9 575/4885TDP1 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.